Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

November 6, 2019

Study Completion Date

November 6, 2019

Conditions
Malignant Melanoma
Interventions
DRUG

Cobimetinib + Vemurafenib combination treatment

Patients will be treated from day 1 to day 28 with Vemurafenib and from day 1 to day 21 with Cobimetinib. Day 1 to Day 28 corresponds to one cycle of treatment.

Trial Locations (17)

14033

CHU Caen - Hôpital Clémenceau, Caen

33000

CHU de Bordeaux, Bordeaux

35042

Centre Eugène Marquis, Rennes

37044

CHU Tours, Tours

38014

CHU Albert Michallon, Grenoble

44093

CHU de Nantes, Nantes

59037

CHRU Lille, Lille

69495

Centre Hospitalier Lyon Sud, Lyon

72037

Centre Hospitalier du Mans, Le Mans

75010

Hôîtal St louis, Paris

75014

Hôpital Cochin, Paris

75018

Hôpital Bichat, Paris

92104

CHU Ambroise Paré, Boulogne

94010

Hôpital Henri Mondor, Créteil

Unknown

CHU Brest - Hôpital Morvan, Brest

CHU de Dijon, Dijon

06202

Groupe Hospitalier l'Archet, Nice

All Listed Sponsors
lead

Center Eugene Marquis

OTHER

NCT02537600 - Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis | Biotech Hunter | Biotech Hunter